Pfizer deal poses challenge to Genzyme
Drug maker pursues share of market for treating rare disorder
Drug giant Pfizer Inc. , mounting a direct challenge to Cambridge biotech Genzyme Corp. , yesterday said it will spend up to $110 million to license the global rights to a treatment being developed for the rare genetic disorder Gaucher disease. (Full article: 879 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
